We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App





New, Highly Accurate, POC Test Measures Level of Neutralizing Antibodies (NAb) to COVID-19, Including Variants

By LabMedica International staff writers
Posted on 22 Dec 2021
Print article
Image: A prototype of the test (Photo courtesy of Burnet Institute)
Image: A prototype of the test (Photo courtesy of Burnet Institute)

A new, highly accurate, point-of-care (POC) test can measure the level of neutralizing antibodies (NAb) to COVID-19, including variants.

The test, developed by scientists at the Burnet Institute (Melbourne, Australia) and the Peter Doherty Institute for Infection and Immunity (Melbourne, Australia), provides a readout from a fingerprick of blood in less than 20 minutes. The test is the first of its type globally, and could also be useful to indicate when a vaccine booster may be required. While there are many POC tests that can measure the overall level of antibody to SARS-CoV-2, and use this to estimate neutralizing antibodies, this is the only test to measure neutralizing antibody activity, which correlates with immune protection from serious disease in COVID-19.

The emergence of the Omicron variant, which early studies suggest may be up to 40-times less sensitive to patient NAb than Delta, means that some people will go from having enough NAb to be protected, to not having enough. The test provides a new option for immunity screening to support COVID-19 vaccination and control programs, particularly in time-critical and low- and middle-income settings where laboratory-based testing is difficult or impossible for many to access.

“One of the key elements of the test is that it can work with fingerprick whole blood, which is essential if it is really going to be used at point-of-care,” said study joint supervising author, Associate Professor David Anderson, Burnet Institute Deputy Director and Chief Scientific Officer of the Burnet Diagnostics Initiative.

“We envisage that this test may be part of a set of indications that will help to determine who may need a booster vaccine,” said Dr. Tom Fulford from the Doherty Institute. “This can also be adapted so that it can provide information about whether an individual has protective antibodies against particular variants of concern.”

Related Links:
Burnet Institute 
Doherty Institute 

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
SARS-CoV-2 (ORF1a, N, RdRp) Real-Time RT-PCR Test
DiaPlexQ SARS-CoV-2 (ORF1a, N, RdRp)
New
WBC Analyzer
HemoCue WBC System
New
Gold Supplier
pHOx Analyzer
BioProfile pHOx Analyzer

Print article

Channels

Molecular Diagnostics

view channel
Image: A new method reliably detects protein changes in blood that are typical of Parkinson`s disease (Photo courtesy of Pexels)

First-Ever Blood Test Detects Parkinson’s Disease

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years... Read more

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.